Validating performance of an Agilent ICP‑MS for USP <232>/<233> & ICH Q3D(R2)/Q2(R1)

Application Note Pharma & Biopharma Analysis of Artificial Tear Eye Drops For Elemental Impurities Using an ICP-MS and USP <232>/<233> and ICH Q3D(R2)/Q2(R1) protocols. Authors Jennifer Sanderson and Lindsey Whitecotton Agilent Technologies, Inc. Introduction As pharmaceutical products are released to…

Application Note Biopharma Analysis of Elemental Impurities in Synthetic Oligonucleotides by ICP-MS Development and testing of an efficient Agilent 7850 ICP-MS method in compliance with USP <232>/<233> and ICH Q3D(R2)/Q2(R1) Authors Introduction Bian Yulan and Li Shuping Synthetic oligonucleotides are…

Validating the Agilent 7700x/7800 ICP-MS for the determination of elemental impurities in pharmaceutical ingredients according to draft USP general chapters <232>/<233> Application note Pharmaceutical Authors Samina Hussain Exova USA Amir Liba and Ed McCurdy Agilent Technologies USA Abstract The United…

Application Note Pharmaceuticals Determining Elemental Impurities in Pharmaceutical Ingredients using ICP-MS USP/ICH methodology used to measure 24 elemental impurities in raw materials dissolved in DMSO Authors Radhey S. Dhuria, Vinay Jain, Gaurav Kapadnis and Samir Vyas Agilent Technologies, Inc. Introduction…